Click to Enlarge
NEXT Pharmaceuticals (Pvt) Ltd as a part of Continued Medical Education (CME) Program organized a lecture on “Rationale of Fixed Dose Combination (FDC) in the management of DM and HTN” at a local hotel in Karachi.
Prof. Dr. M. A. Ebrahim, Consultant Endocrinologist was the Guest Speaker while Physician & Heart Specialist, Prof. Dr. S. M. Rab and Chairman Department of Medicine Ziauddin Medical University, Prof. Dr. Ejaz Ahmed Vohra chaired the session. It was attended by a large number of consultant physicians, cardiologists &Family Physicians.
The aim of the program was to gather diabetologists, Endocrinologists and Family Physician and update them on the basis for using Fixed Dose Combination (FDC) in the management of chronic diseases like DM and HTN. Fixed Dose Combinations decrease the risk of medication non-compliance and should be considered in patients with chronic conditions like hypertension and diabetes mellitus.
Prof. Dr. M. A. Ebrahim speaking on the occasion said that Hypertension and diabetes are major risk factors for cardiovascular diseases and a rise in the prevalence of these risk factors is contributing to the high incidence of CVD.
Dr. Shahzad Qureshi, General Manager Sales & Marketing, NEXT Pharmaceutical gave a brief introduction of the company. He said that NEXT Pharmaceutical aspires to be the leading pharmaceutical company of Pakistan, aiming to provide high quality products at affordable price.
The need for the quality products at affordable price is indeed growing both within Pakistan as well as in the international market. Pakistan being a strategic link between the Middle East and the South East Asia has a great potential to export quality products to the surrounding countries. NEXT Pharmaceutical aspires to develop the state of the art cGMP production facility in Pakistan to ensure the production of the highest quality pharmaceutical products to cater to the local and international needs.
Earlier, TanveerSadiq , Marketing Manager & Ms. Rabea Ijaz, Product Manager Next Pharmaceuticals introduced GLIMIN (a combination of Gliclazide and Metformin for diabetes) and AMPER ( a combination of Amlodipine & Perindopril for hypertension) to the participants.
The chairpersons of the session appreciated Next Pharmaceuticals for arranging the CME program for medical community.